Muhammad Sameed
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Muhammad Sameed has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
A.R. Cucci
Pulmonary & Critical Care, Cleveland Clinic Akron General, Akron, OH, United States
1 shared publicationChristine Nwaiser
Medical School, American University of Antigua College of Medicine, Osbourn, Antigua and Barbuda
1 shared publicationEllen T Marciniak
Pulmonary and Critical Care Medicine, University of Maryland Medical Center, Baltimore, Maryland, USA
1 shared publicationEllen T. Marciniak
Dept of Internal Medicine, University of Maryland Medical Center Midtown, Baltimore, MD, USA
1 shared publicationG.A. Heresi
Respiratory Inst, Cleveland Clinic, Cleveland, OH, United States
1 shared publicationHeidi Teague
Department of Emergency Medicine, University of Maryland Medical System, Midtown Campus, Baltimore, MD, USA
1 shared publication
Latest Publications
- Open Access
- 2 November 2026
- Published by Wiley in Clinical and Translational Science
- Vol. 19 (11)
Treprostinil: Mechanism of Action, Clinical, and Translational Science
Treprostinil is a synthetic prostacyclin analogue with a tricyclic benzindene structure that confers markedly enhanced metabolic stability relative to native prostacyclin, enabling delivery by four distinct routes—intravenous, subcutaneous, inhaled, and oral—that together constitute a mainstay of pharmacotherapy for pulmonary arterial hypertension (PAH). Herein, we review the mechanism of action, pharmacokinetic/pharmacodynamic (PK/PD) characteristics, and clinical development of treprostinil, with primary emphasis on its well‐established role in PAH, including detailed dosing and PK data across all four approved routes, and secondary emphasis on its recently approved role in pulmonary hypertension associated with interstitial lung disease (PH‐ILD) and its investigational, plausible‐future role in idiopathic pulmonary fibrosis (IPF) without a pulmonary hypertension requirement. Treprostinil activates the Gαs‐coupled prostacyclin (IP) receptor to generate a sustained nuclear cyclic adenosine monophosphate (cAMP) signal that is qualitatively distinct from earlier prostacyclin analogues, underlying both its established vasodilatory, antiproliferative, and antiplatelet effects in PAH and a mechanistic hypothesis of antifibrotic activity relevant to IPF. Treprostinil also engages the prostaglandin EP₂ and DP₁ receptors and peroxisome proliferator‐activated receptors, and inhibits transforming growth factor‐β (TGF‐β)‐driven extracellular matrix synthesis through mechanisms only partially explained by cAMP magnitude. Across the four approved routes, treprostinil exhibits route‐specific pharmacokinetics—near‐complete subcutaneous bioavailability with a 4‐hour terminal half‐life, oral bioavailability of approximately 17% with extensive first‐pass CYP2C8 metabolism, and inhaled systemic bioavailability of approximately 64%–72%—that inform the distinct dosing and titration strategies detailed in this review. In a plausible, still‐investigational extension of this pharmacology beyond PAH, two replicate Phase 3 trials (TETON‐1 and TETON‐2) have reported that inhaled treprostinil reduces the decline in forced vital capacity (FVC) and the risk of clinical worsening in patients with IPF without a pulmonary hypertension requirement. These findings support a plausible antifibrotic hypothesis pending confirmatory evidence and regulatory review; treprostinil is not currently approved for an IPF indication, and this signal should be interpreted as hypothesis‐generating rather than establishing disease modification.
- 2 November 2026
- Published by Wiley in Clinical and Translational Science
- Vol. 19 (11)
Open AccessTreprostinil: Mechanism of Action, Clinical, and Translational Science
Treprostinil is a synthetic prostacyclin analogue with a tricyclic benzindene structure that confers markedly enhanced metabolic stability relative to native prostacyclin, enabling delivery by four distinct routes—intravenous, subcutaneous, inhaled, and oral—that together constitute a mainstay of pharmacotherapy for pulmonary arterial hypertension (PAH). Herein, we review the mechanism of action, pharmacokinetic/pharmacodynamic (PK/PD) characteristics, and clinical development of treprostinil, with primary emphasis on its well‐established role in PAH, including detailed dosing and PK data across all four approved routes, and secondary emphasis on its recently approved role in pulmonary hypertension associated with interstitial lung disease (PH‐ILD) and its investigational, plausible‐future role in idiopathic pulmonary fibrosis (IPF) without a pulmonary hypertension requirement. Treprostinil activates the Gαs‐coupled prostacyclin (IP) receptor to generate a sustained nuclear cyclic adenosine monophosphate (cAMP) signal that is qualitatively distinct from earlier prostacyclin analogues, underlying both its established vasodilatory, antiproliferative, and antiplatelet effects in PAH and a mechanistic hypothesis of antifibrotic activity relevant to IPF. Treprostinil also engages the prostaglandin EP₂ and DP₁ receptors and peroxisome proliferator‐activated receptors, and inhibits transforming growth factor‐β (TGF‐β)‐driven extracellular matrix synthesis through mechanisms only partially explained by cAMP magnitude. Across the four approved routes, treprostinil exhibits route‐specific pharmacokinetics—near‐complete subcutaneous bioavailability with a 4‐hour terminal half‐life, oral bioavailability of approximately 17% with extensive first‐pass CYP2C8 metabolism, and inhaled systemic bioavailability of approximately 64%–72%—that inform the distinct dosing and titration strategies detailed in this review. In a plausible, still‐investigational extension of this pharmacology beyond PAH, two replicate Phase 3 trials (TETON‐1 and TETON‐2) have reported that inhaled treprostinil reduces the decline in forced vital capacity (FVC) and the risk of clinical worsening in patients with IPF without a pulmonary hypertension requirement. These findings support a plausible antifibrotic hypothesis pending confirmatory evidence and regulatory review; treprostinil is not currently approved for an IPF indication, and this signal should be interpreted as hypothesis‐generating rather than establishing disease modification.
- 1 May 2023
- Published by Oxford University Press (OUP)
- p. A5542
Utility of Pulmonary Function Testing in Detection of Pulmonary Hypertension in COPD
- 1 May 2023
- Published by Oxford University Press (OUP)
- p. A5542
Utility of Pulmonary Function Testing in Detection of Pulmonary Hypertension in COPD
- Open Access
- 3 September 2019
- Published by Greater Baltimore Medical Center in Journal of Community Hospital Internal Medicine Perspectives
- Vol. 9 (5) , 422-424
Use of nebulized naloxone to reverse methadone overdose – A case report and review of literature
Opioid use is a frequent cause of morbidity and mortality in the USA. We report a case of methadone overdose reversed with naloxone nebulization. Peripheral IV access can be difficult to obtain in patients with a history of IV drug abuse making needless routes of naloxone administration useful. When naloxone is administered as a bolus, chronically opioid dependent patients are more prone to violent withdrawal symptoms. When successful, nebulized naloxone reverses intoxication and allows the patient to self-titrate the discontinuation of naloxone when they are alert enough to remove the mask. Nebulized naloxone can provide needleless and noninvasive administration for the reversal of opioid overdose.
- 3 September 2019
- Published by Greater Baltimore Medical Center in Journal of Community Hospital Internal Medicine Perspectives
- Vol. 9 (5) , 422-424
Open AccessUse of nebulized naloxone to reverse methadone overdose – A case report and review of literature
Opioid use is a frequent cause of morbidity and mortality in the USA. We report a case of methadone overdose reversed with naloxone nebulization. Peripheral IV access can be difficult to obtain in patients with a history of IV drug abuse making needless routes of naloxone administration useful. When naloxone is administered as a bolus, chronically opioid dependent patients are more prone to violent withdrawal symptoms. When successful, nebulized naloxone reverses intoxication and allows the patient to self-titrate the discontinuation of naloxone when they are alert enough to remove the mask. Nebulized naloxone can provide needleless and noninvasive administration for the reversal of opioid overdose.
- Open Access
- 1 September 2019
- Published by European Respiratory Society (ERS) in Breathe
- Vol. 15 (3) , 244-246
EOLIA trial: the future of extracorporeal membrane oxygenation in acute respiratory distress syndrome therapy?
In the EOLIA trial, early use of ECMO did not significantly improve mortality at 60 days in patients with severe ARDS, but when used as a rescue modality ECMO might help improve survivalhttp://bit.ly/2XOjwSE
- 1 September 2019
- Published by European Respiratory Society (ERS) in Breathe
- Vol. 15 (3) , 244-246
Open AccessEOLIA trial: the future of extracorporeal membrane oxygenation in acute respiratory distress syndrome therapy?
In the EOLIA trial, early use of ECMO did not significantly improve mortality at 60 days in patients with severe ARDS, but when used as a rescue modality ECMO might help improve survivalhttp://bit.ly/2XOjwSE
- 20 August 2019
- Published by BMJ in BMJ Case Reports
- Vol. 12 (8) , e230144
Meropenem-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in a patient with known type IV penicillin hypersensitivity
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are considered variants of a disease continuum that results in a life-threatening exfoliative mucocutaneous disease. These are categorised as type IV cell-mediated delayed hypersensitivity reactions, and antibiotics are often implicated as a cause. Penicillins and other beta-lactam antibiotics are known to cause both immediate and delayed hypersensitivity reactions. While immediate IgE-mediated cross-reactivity between penicillins and carbapenems is well studied, less information on the risk of type IV delayed cell-mediated cross-reactivity between the two is available. We present a case of meropenem-induced SJS in a patient with documented history of SJS from amoxicillin. There are few cases of cross-reactivity with carbapenems reported in the literature, but based on the potential for life-threatening reaction, it is likely prudent to avoid the use of any beta-lactams in a patient with a history of SJS, TEN or any other severe cutaneous adverse reactions to another beta-lactam antibiotic.
- 20 August 2019
- Published by BMJ in BMJ Case Reports
- Vol. 12 (8) , e230144
Meropenem-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in a patient with known type IV penicillin hypersensitivity
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are considered variants of a disease continuum that results in a life-threatening exfoliative mucocutaneous disease. These are categorised as type IV cell-mediated delayed hypersensitivity reactions, and antibiotics are often implicated as a cause. Penicillins and other beta-lactam antibiotics are known to cause both immediate and delayed hypersensitivity reactions. While immediate IgE-mediated cross-reactivity between penicillins and carbapenems is well studied, less information on the risk of type IV delayed cell-mediated cross-reactivity between the two is available. We present a case of meropenem-induced SJS in a patient with documented history of SJS from amoxicillin. There are few cases of cross-reactivity with carbapenems reported in the literature, but based on the potential for life-threatening reaction, it is likely prudent to avoid the use of any beta-lactams in a patient with a history of SJS, TEN or any other severe cutaneous adverse reactions to another beta-lactam antibiotic.
- 16 April 2019
- Published by BMJ in BMJ Case Reports
- Vol. 12 (4) , e228741
Chronic cough and cystic lung disease caused by Bordetella bronchiseptica in a patient with AIDS
A 24-year-old man with a history of HIV and large B cell lymphoma (currently in remission) presented with fever, dry cough and dizziness. His CD4+ count was undetectable, and the HIV viral load was 109 295 cop/mL. Physical examination revealed fever, hypotension and tachycardia with coarse breath sounds in the middle and lower chest zones bilaterally. Chest imaging showed diffuse abnormal micronodular and patchy infiltrates, without focal consolidation. A cavitary lesion was noted measuring 5×2 cm in axial dimensions within the left lower lobe and multiple small cystic lesions in the background. Bronchoalveolar lavage fluid culture grew Bordetella bronchiseptica. The patient was empirically treated with vancomycin and piperacillin–tazobactam for multifocal pneumonia with concerns for sepsis and was started on combined antiretroviral therapy (cART) with abacavir/dolutegravir/lamivudine. Symptoms improved after day 3 of therapy, and the patient was discharged home on 2 weeks of moxifloxacin, in addition to the cART and appropriate chemoprophylaxis.
- 16 April 2019
- Published by BMJ in BMJ Case Reports
- Vol. 12 (4) , e228741
Chronic cough and cystic lung disease caused by Bordetella bronchiseptica in a patient with AIDS
A 24-year-old man with a history of HIV and large B cell lymphoma (currently in remission) presented with fever, dry cough and dizziness. His CD4+ count was undetectable, and the HIV viral load was 109 295 cop/mL. Physical examination revealed fever, hypotension and tachycardia with coarse breath sounds in the middle and lower chest zones bilaterally. Chest imaging showed diffuse abnormal micronodular and patchy infiltrates, without focal consolidation. A cavitary lesion was noted measuring 5×2 cm in axial dimensions within the left lower lobe and multiple small cystic lesions in the background. Bronchoalveolar lavage fluid culture grew Bordetella bronchiseptica. The patient was empirically treated with vancomycin and piperacillin–tazobactam for multifocal pneumonia with concerns for sepsis and was started on combined antiretroviral therapy (cART) with abacavir/dolutegravir/lamivudine. Symptoms improved after day 3 of therapy, and the patient was discharged home on 2 weeks of moxifloxacin, in addition to the cART and appropriate chemoprophylaxis.